BACKGROUND: Unresectable intrahepatic and @entity201 carry a dismal prognosis. Systemic chemotherapy and conventional external beam radiation and brachytherapy have been used with limited success. We explored the use of stereotactic body radiotherapy (SBRT) for these @entity1 . METHODS: @entity1 with unresectable @entity1419 or those with positive margins were included in this study. Systemic therapy was used at the discretion of the medical oncologist. The Cyberknife(TM) stereotactic body radiotherapy system used to treat these @entity1 . @entity1 were treated with three daily fractions. Clinical and radiological follow-up were performed every three months. RESULTS: 34 @entity1 (16 male and 18 female) with 42 lesions were included in this study. There were 32 unresectable @entity5 and two @entity1 with @entity5 with positive margins. The median SBRT dose was 30Gy in three fractions. The median follow-up was 38 months (range 8-71 months). The actuarial local control rate was 79%. The median overall survival was 17 months and the median progression free survival was ten months. There were four Grade III @entity137 (12%), including duodenal ulceration, @entity255 and @entity5572 . CONCLUSIONS: SBRT is an effective and reasonably safe local therapy option for unresectable @entity1419 .

Stereotactic Body Radiotherapy (SBRT) for XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity5572 :: ('MESH:D008100', 'Disease') :: ['liver abscess'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity5 :: ('MESH:D009369', 'Disease') :: ['resected tumors', 'tumors'] @entity201 :: ('MESH:D018281', 'Disease') :: ['hilar cholangiocarcinomas'] @entity1419 :: ('MESH:C535533', 'Disease') :: ['intrahepatic or hilar cholangiocarcinoma'] @entity255 :: ('MESH:D002761', 'Disease') :: ['cholangitis']
@entity1419 :: (MESH:C535533,Disease) :: ['Intrahepatic and Hilar Cholangiocarcinoma']
